Skip to content

KMTS KMTS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Boston Scientific logo
Boston ScientificBSX
$21.58B+2.2%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$1B+11.4%
Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
ICU Medical logo
ICU MedicalICUI
$1.47B+3.5%
Edwards Lifesciences logo
Edwards LifesciencesEW
$2.78B+4.8%
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$24.6M+62.7%
Gross profit$12.9M+97.1%
Operating income-$34.8M-68.8%
Net income-$34.2M-58.8%
EPS (diluted)-$0.61+51.2%

Balance sheet

See full
Cash & equivalents$291.3M+436%
Total debt$43.8M
Total assets$379.3M

Cash flow

See full
Operating cash flow-$18.4M-2.1%
CapEx$9.8M+141%
Free cash flow-$28.2M-27.7%

Valuation

See full
Market cap$1.32B+70.8%
Enterprise value$1.07B
P/S15.7×

Profitability

See full
Gross margin48.8%+15.1pp
Operating margin-171.5%+12.9pp
Net margin-173%+0.8pp
FCF margin-142.9%-25.3pp

Returns & leverage

See full
Current ratio7.3×

Where this comes from

Reported directly by KMTS in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: KMTS’s 10-Q, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about KMTS's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KMTS's additional paid-in capital?
KMTS (KMTS) reported additional paid-in capital of $842.67M in Q4 2025.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.